- Home
- / Portola Pharmaceuticals
Portola Pharmaceuticals
Revenue
$116.6 M
FY, 2019
Portola Pharmaceuticals Summary
Company Summary
- Overview
- Portola Pharmaceuticals is a biopharmaceutical company. It develops therapies to treat thrombosis and other hematologic diseases. Portola is dedicated to the discovery and development of medicines for patients with thrombosis and hematologic cancers. The Company provides two medicines: Andexxa and Bevyxxa.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2003
- HQ
- South San Francisco, CA, US | view all locations
- Website
- https://www.portola.com
- Cybersecurity rating
Table of Contents
Key People
Mardi C. Dier, Executive Vice President, Chief Financial Officer and Chief Business Officer
Sheldon Koenig, Executive Vice President, Chief Commercial Officer
Ernie Meyer, Executive Vice President, Chief Human Resources Officer
LocationsView all
3 locations detected
South San Francisco, CA HQ
United States
270 E Grand Ave
Planegg, BY
Germany
Fraunhoferstraße 12
Amsterdam, NH
Netherlands
Prins Bernhardplein 200
Portola Pharmaceuticals Financials
Summary Financials
- Revenue (Q1, 2020)
- $26.4M
- Gross profit (Q1, 2020)
- $22.1M
- Net income (Q1, 2020)
- ($68.8M)
- Cash (Q1, 2020)
- $196.2M
- EBIT (Q1, 2020)
- ($58.4M)